What Is Semaglutide?

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) — a hormone naturally released by L-cells in the gut after meals. The molecule was engineered by Novo Nordisk with a C18 fatty-acid chain attached via a linker, allowing it to bind albumin in the bloodstream. This albumin binding dramatically extends its half-life to approximately 7 days, enabling once-weekly dosing.

Semaglutide is the active ingredient in two branded products: Ozempic (0.25–1mg, approved for type 2 diabetes) and Wegovy (0.25–2.4mg, approved for chronic weight management). The same molecule at different maximum doses and indications. Since its patent expiration, Indian pharmaceutical companies launched generics in March 2026, dramatically improving access.

Beyond weight loss, semaglutide has demonstrated significant cardiovascular benefits in the SUSTAIN-6 and SELECT trials, reducing major adverse cardiovascular events (MACE) by 20–26% independent of weight loss.

Mechanism of Action

Semaglutide works through three primary mechanisms that together produce its metabolic effects:

• Appetite suppression via hypothalamic GLP-1 receptors: GLP-1 receptors in the arcuate nucleus and other appetite-regulating brain regions are directly activated by semaglutide. This reduces hunger signals, increases satiety, and shifts food preferences away from high-calorie options. This central effect accounts for the majority of weight loss.
• Slowed gastric emptying: Semaglutide delays the rate at which food leaves the stomach, extending the feeling of fullness after meals and flattening post-meal glucose spikes. This also contributes to nausea, particularly in the first weeks of treatment.
• Glucose-dependent insulin secretion: In the pancreas, semaglutide enhances insulin release from beta cells — but only when blood glucose is elevated. This glucose-dependence means it does not cause hypoglycemia at therapeutic doses. It also suppresses glucagon from alpha cells, reducing hepatic glucose output.

The net result is a significant reduction in caloric intake (studies show 30–50% fewer calories consumed), improved insulin sensitivity, and better glycemic control. For deeper mechanistic reading, the original SUSTAIN-1 trial on PubMed provides the foundational clinical data.

Weight Loss Mechanism

The primary driver of weight loss on semaglutide is reduced energy intake. Studies using doubly-labelled water show that people on 2.4mg semaglutide consume roughly 30–35% fewer calories without conscious effort. This is not willpower — it is a pharmacological reduction in appetite drive.

At the 0.5–1mg Ozempic doses, average weight loss is 5–12% of body weight. At the 2.4mg Wegovy dose, the STEP-1 trial demonstrated 14.9% average weight loss, with a third of participants losing over 20%. Weight loss typically continues for 12–20 weeks before plateauing, and is largely regained if the drug is stopped — indicating ongoing metabolic support rather than a "cure."

India Generic Launch — March 2026

Semaglutide's core patents expired in early 2026, triggering a wave of generic launches by Indian pharmaceutical manufacturers. Three companies received CDSCO approval:

Dosing & Titration Protocol

Semaglutide is titrated slowly to minimize gastrointestinal side effects. The standard titration follows a 4-week step-up schedule:

1. Weeks 1–4: 0.25mg once weekly (this is a ramp-up dose, not a therapeutic dose)
2. Weeks 5–8: 0.5mg once weekly (therapeutic for diabetes in many patients)
3. Weeks 9–12: 1mg once weekly (standard diabetes dose, some weight loss benefit)
4. Weeks 13–16: 1.7mg once weekly (Wegovy titration only)
5. Week 17+: 2.4mg once weekly (full Wegovy dose — maximum weight loss efficacy)

The drug is injected subcutaneously — typically into the abdomen, thigh, or upper arm — once per week on the same day each week. Rotate injection sites to prevent lipohypertrophy. Store pens at 2–8°C (refrigerated) until first use, then at room temperature for up to 56 days. India's heat requires attention to cold-chain storage — never leave pens in a car or non-air-conditioned room.

Biomarker Connections — What to Test

Before starting:

• HbA1c — establishes your glycemic baseline; significant improvement expected in 3 months
• Fasting insulin + HOMA-IR — documents insulin resistance level before treatment
• Fasting lipids + ApoB — semaglutide modestly improves LDL and triglycerides; ApoB tracks atherogenic particle burden
• Ferritin — reduced meat intake on the drug may deplete iron over time
• Vitamin B12 — baseline before reduced dietary intake begins
• Amylase and lipase — pancreatic enzyme baseline (rare pancreatitis risk)
• Thyroid (TSH) — contraindicated in medullary thyroid carcinoma history

While on treatment (every 3 months initially):

• Body weight and waist circumference (aim for 1% body weight/week maximum)
• HbA1c (expect 1–2% reduction if starting from elevated levels)
• Fasting glucose and fasting insulin
• Lipid panel with ApoB
• B12 annually — especially if eating significantly less meat or dairy

Side Effects

The most common side effects are gastrointestinal and are dose-dependent:

• Nausea (40–50% of users, typically weeks 1–8) — manageable with slow titration, small meals, and ginger
• Vomiting (10–25%) — usually accompanies nausea; severe cases may require dose reduction
• Diarrhea or constipation (20–30%) — adequate hydration and fibre important
• Gallbladder issues — rapid weight loss increases cholelithiasis (gallstone) risk; watch for right upper quadrant pain
• Muscle loss — see warning box above

Rare but serious: acute pancreatitis (discontinue immediately if severe abdominal pain develops). Contraindicated in personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2).

Frequently Asked Questions

Related Terms